Keywords: Amgen, AMG 145, Cholesterol, PCSK9 inhibitors, LDL-C, Pfizer, RN316

Strong mid-stage results for Amgen's cholesterol drug candidate AMG 145

Article | 07 November 2012

Print This

Global biotech leader Amgen (Nasdaq: AMGN) has announced positive results from the AMG 145 Phase II GAUSS study, in patients with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in